Why Minnesota Created a Public Option for Generic Drugs

In May 2026, Minnesota launched the country's first state-run generic drug manufacturing program, aiming to break monopolies on price-inflated generics. Lucas and Luna dig into how the state identified three drugs where prices had jumped 400% in five years, tracing the supply-chain bottlenecks that let a single middleman control 80% of a market. They explore the legal structure—a state-owned factory leased to a nonprofit—and why the pharmaceutical lobby calls it 'government overreach' while patient advocates say it's the only antidote to price-gouging middlemen. The episode also touches on how this 'public option for pills' fits into a growing movement by states to bypass the three pharmacy benefit managers that process nearly 80% of all US prescriptions. Specific numbers include: the $50 million initial investment, the 30-month timeline to first production, and the 90-day supply cost savings target of 60% below current retail. #Minnesota #GenericDrugs #PublicOption #PharmacyBenefitManagers #StateManufacturing #DrugPricing #PharmaceuticalLobby #PBMs #AlecGustafson #AminGulati #CostPlusDrugs #MarkCuban #GenericDrugManufacturing #HealthcareEconomics #Economics #FexingoBusiness #BusinessPodcast #FiscalPolicy Keep every episode free: buymeacoffee.com/fexingo